Literature DB >> 27017608

Delivery of Therapeutic Proteins via Extracellular Vesicles: Review and Potential Treatments for Parkinson's Disease, Glioma, and Schwannoma.

Justin Hall1,2, Shilpa Prabhakar2, Leonora Balaj2, Charles P Lai2,3, Richard A Cerione1, Xandra O Breakefield4,5.   

Abstract

Extracellular vesicles present an attractive delivery vehicle for therapeutic proteins. They intrinsically contain many proteins which can provide information to other cells. Advantages include reduced immune reactivity, especially if derived from the same host, stability in biologic fluids, and ability to target uptake. Those from mesenchymal stem cells appear to be intrinsically therapeutic, while those from cancer cells promote tumor progression. Therapeutic proteins can be loaded into vesicles by overexpression in the donor cell, with oligomerization and membrane sequences increasing their loading. Examples of protein delivery for therapeutic benefit in pre-clinical models include delivery of: catalase for Parkinson's disease to reduce oxidative stress and thus help neurons to survive; prodrug activating enzymes which can convert a prodrug which crosses the blood-brain barrier into a toxic chemotherapeutic drug for schwannomas and gliomas; and the apoptosis-inducing enzyme, caspase-1 under a Schwann cell specific promoter for schwannoma. This therapeutic delivery strategy is novel and being explored for a number of diseases.

Entities:  

Keywords:  Exosomes; Extracellular vesicles; Glioma; Parkinson’s disease; Schwannoma; Therapeutic protein delivery

Mesh:

Substances:

Year:  2016        PMID: 27017608      PMCID: PMC4860146          DOI: 10.1007/s10571-015-0309-0

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  80 in total

1.  Dynamics of intracellular granules with CD63-GFP in rat basophilic leukemia cells.

Authors:  T Amano; T Furuno; N Hirashima; N Ohyama; M Nakanishi
Journal:  J Biochem       Date:  2001-05       Impact factor: 3.387

2.  Protein targeting to exosomes/microvesicles by plasma membrane anchors.

Authors:  Beiyi Shen; Ning Wu; Jr-Ming Yang; Stephen J Gould
Journal:  J Biol Chem       Date:  2011-02-07       Impact factor: 5.157

3.  Differential fates of biomolecules delivered to target cells via extracellular vesicles.

Authors:  Masamitsu Kanada; Michael H Bachmann; Jonathan W Hardy; Daniel Omar Frimannson; Laura Bronsart; Andrew Wang; Matthew D Sylvester; Tobi L Schmidt; Roger L Kaspar; Manish J Butte; A C Matin; Christopher H Contag
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-23       Impact factor: 11.205

4.  Regression of schwannomas induced by adeno-associated virus-mediated delivery of caspase-1.

Authors:  Shilpa Prabhakar; Mehran Taherian; Davide Gianni; Thomas J Conlon; Giulia Fulci; Jillian Brockmann; Anat Stemmer-Rachamimov; Miguel Sena-Esteves; Xandra O Breakefield; Gary J Brenner
Journal:  Hum Gene Ther       Date:  2013-01-30       Impact factor: 5.695

5.  Establishment and characterization of a schwannoma cell line from a patient with neurofibromatosis 2.

Authors:  Gene Hung; Xiankui Li; Rodolfo Faudoa; Zhu Xeu; Lan Kluwe; Johng S Rhim; William Slattery; David Lim
Journal:  Int J Oncol       Date:  2002-03       Impact factor: 5.650

6.  Exosomes derived from IL-12-anchored renal cancer cells increase induction of specific antitumor response in vitro: a novel vaccine for renal cell carcinoma.

Authors:  Yao Zhang; Chun-Li Luo; Bai-Cheng He; Jia-Mo Zhang; Gang Cheng; Xiao-Hou Wu
Journal:  Int J Oncol       Date:  2010-01       Impact factor: 5.650

7.  A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy.

Authors:  Yanhua Tian; Suping Li; Jian Song; Tianjiao Ji; Motao Zhu; Gregory J Anderson; Jingyan Wei; Guangjun Nie
Journal:  Biomaterials       Date:  2013-12-15       Impact factor: 12.479

8.  Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor.

Authors:  C A Mullen; M M Coale; R Lowe; R M Blaese
Journal:  Cancer Res       Date:  1994-03-15       Impact factor: 12.701

Review 9.  The application of exosomes as a nanoscale cancer vaccine.

Authors:  Aaron Tan; Hugo De La Peña; Alexander M Seifalian
Journal:  Int J Nanomedicine       Date:  2010-11-10

10.  MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins.

Authors:  Kasey C Vickers; Brian T Palmisano; Bassem M Shoucri; Robert D Shamburek; Alan T Remaley
Journal:  Nat Cell Biol       Date:  2011-03-20       Impact factor: 28.824

View more
  35 in total

Review 1.  Neuropharmacologic Approaches to Restore the Brain's Microenvironment.

Authors:  Weizhe Li; Hsin-I Tong; Santhi Gorantla; Larisa Y Poluektova; Howard E Gendelman; Yuanan Lu
Journal:  J Neuroimmune Pharmacol       Date:  2016-06-28       Impact factor: 4.147

Review 2.  Viral vectors for therapy of neurologic diseases.

Authors:  Sourav R Choudhury; Eloise Hudry; Casey A Maguire; Miguel Sena-Esteves; Xandra O Breakefield; Paola Grandi
Journal:  Neuropharmacology       Date:  2016-02-21       Impact factor: 5.250

Review 3.  Organophosphate neurotoxicity to the voluntary motor system on the trail of environment-caused amyotrophic lateral sclerosis: the known, the misknown, and the unknown.

Authors:  Samantha J Merwin; Teresa Obis; Yanelli Nunez; Diane B Re
Journal:  Arch Toxicol       Date:  2017-01-09       Impact factor: 5.153

Review 4.  Extracellular vesicle docking at the cellular port: Extracellular vesicle binding and uptake.

Authors:  Kinsley C French; Marc A Antonyak; Richard A Cerione
Journal:  Semin Cell Dev Biol       Date:  2017-01-16       Impact factor: 7.727

Review 5.  Genetic-Driven Druggable Target Identification and Validation.

Authors:  Matteo Floris; Stefania Olla; David Schlessinger; Francesco Cucca
Journal:  Trends Genet       Date:  2018-05-23       Impact factor: 11.639

6.  Measurement and standardization challenges for extracellular vesicle therapeutic delivery vectors.

Authors:  Bryant C Nelson; Samantha Maragh; Ionita C Ghiran; Jennifer C Jones; Paul C DeRose; Elzafir Elsheikh; Wyatt N Vreeland; Lili Wang
Journal:  Nanomedicine (Lond)       Date:  2020-09-04       Impact factor: 5.307

Review 7.  The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease.

Authors:  Elma Aflaki; Wendy Westbroek; Ellen Sidransky
Journal:  Neuron       Date:  2017-02-22       Impact factor: 17.173

8.  Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2.

Authors:  Shilpa Prabhakar; Roberta L Beauchamp; Pike See Cheah; Akiko Yoshinaga; Edwina Abou Haidar; Sevda Lule; Gayathri Mani; Katia Maalouf; Anat Stemmer-Rachamimov; David H Jung; D Bradley Welling; Marco Giovannini; Scott R Plotkin; Casey A Maguire; Vijaya Ramesh; Xandra O Breakefield
Journal:  Mol Ther Methods Clin Dev       Date:  2022-06-22       Impact factor: 5.849

Review 9.  Potential of Extracellular Vesicles in Neurodegenerative Diseases: Diagnostic and Therapeutic Indications.

Authors:  Mehrnaz Izadpanah; Arshia Seddigh; Somayeh Ebrahimi Barough; Seyed Abolhassan Shahzadeh Fazeli; Jafar Ai
Journal:  J Mol Neurosci       Date:  2018-08-23       Impact factor: 3.444

10.  Therapeutic Potential of Extracellular Vesicles for Sepsis Treatment.

Authors:  Stephanie M Kronstadt; Alex E Pottash; Daniel Levy; Sheng Wang; Wei Chao; Steven M Jay
Journal:  Adv Ther (Weinh)       Date:  2021-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.